Princeton-based Advaxis Inc., a biotechnology company focused on immunotherapy products, announced Monday that Robert Petit will be departing from his role as chief scientific officer at the end of May.
Petit will assist the Princeton-based firm during the transition and will continue as an advisor and consultant as the new chair of the Advaxis Scientific Advisory Board, effective June 3.
“Advaxis’ clinical and preclinical programs have grown and matured significantly during Dr. Petit’s time with the Company, and we are grateful for his guidance and expertise as chief scientific officer. Over the past several years our business has transitioned from research and validation to one with a product portfolio featuring multiple programs in various stages of clinical development. We appreciate Robert’s work in bringing us to this point,” Kenneth A. Berlin, CEO and president of Advaxis, said.
“On behalf of Advaxis, I would like to thank Robert for his scientific leadership and extensive contributions to the company’s progress. We look forward to his continued support as chair of our Scientific Advisory Board.”
Petit said, “It is with mixed emotions that I leave my role as the chief scientific officer, however, I am excited to continue providing scientific guidance to Advaxis as we progress toward clinical validation of the platform in furtherance of Advaxis’ mission to improve the lives of people with cancer.”
